Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Mayumi Fujita

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-DERM General Operations
Phone303/724-4045

    Collapse Research 
    Collapse research activities and funding
    R03CA125833     (FUJITA, MAYUMI)Sep 8, 2008 - Aug 31, 2011
    NIH
    Developing a protocol for profiling blood markers of melanoma
    Role: Principal Investigator

    I01BX001228     (FUJITA, MAYUMI)Jul 1, 2012 - Sep 30, 2021
    NIH
    Autoinflammation in Human Melanoma
    Role: Principal Investigator

    R01CA197919     (FUJITA, MAYUMI)Mar 1, 2016 - Feb 28, 2021
    NIH
    Modulation of inflammasome-mediated cytokine activation by EGCG in human melanoma.
    Role: Principal Investigator

    R01AI156534     (FUJITA, MAYUMI)Jul 6, 2021 - Jun 30, 2026
    NIH
    The role of IL-37 in human regulatory T cells
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021 03 09; 118(10). PMID: 33649199.
      View in: PubMed
    2. Rundle CW, Rietcheck HR, Maghfour J, Dercon S, Fernandez J, Lio P, Dellavalle RP, Fujita M, Yardley H. Anti-inflammatory Effect of Cannabidiol and Palmitoylethanolamide Containing Topical Formulation on Skin in a 12-O-Tetradecanoylphorbol-13-Acetate-Induced Dermatitis Model in Mice. Dermatitis. 2021 Mar 04. PMID: 33654018.
      View in: PubMed
    3. Zhai Z, Vaddi PK, Samson JM, Takegami T, Fujita M. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Pharmaceuticals (Basel). 2020 Dec 30; 14(1). PMID: 33396632.
      View in: PubMed
    4. de Graaf DM, Jaeger M, van den Munckhof ICL, Ter Horst R, Schraa K, Zwaag J, Kox M, Fujita M, Yamauchi T, Mercurio L, Madonna S, Rutten JHW, de Graaf J, Riksen NP, van de Veerdonk FL, Netea MG, Joosten LAB, Dinarello CA. Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. Eur J Immunol. 2021 03; 51(3):662-671. PMID: 33125159.
      View in: PubMed
    5. Samson JM, Ravindran Menon D, Vaddi PK, Kalani Williams N, Domenico J, Zhai Z, Backos DS, Fujita M. Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes. Front Immunol. 2020; 11:584364. PMID: 33329557.
      View in: PubMed
    6. Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, Ravindran Menon D, Fujita M. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers (Basel). 2020 Sep 04; 12(9). PMID: 32899791.
      View in: PubMed
    7. Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. J Invest Dermatol. 2021 03; 141(3):638-647.e13. PMID: 32800877.
      View in: PubMed
    8. Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020 Aug 05; 12(8). PMID: 32764384.
      View in: PubMed
    9. Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443. PMID: 32513939.
      View in: PubMed
    10. Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020; 10(14):6261-6277. PMID: 32483452.
      View in: PubMed
    11. Anwar A, Anwar H, Yamauchi T, Tseng R, Agarwal R, Horwitz LD, Zhai Z, Fujita M. Bucillamine Inhibits UVB-Induced MAPK Activation and Apoptosis in Human HaCaT Keratinocytes and SKH-1 Hairless Mouse Skin. Photochem Photobiol. 2020 07; 96(4):870-876. PMID: 32077107.
      View in: PubMed
    12. Samson JM, Ravindran Menon D, Smith DE, Baird E, Kitano T, Gao D, Tan AC, Fujita M. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Chem Biol Interact. 2019 Dec 01; 314:108822. PMID: 31580832.
      View in: PubMed
    13. Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M, Beckman K, Fujita M, Fischer S, Dinarello CA. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 09; 20(9):1138-1149. PMID: 31427775.
      View in: PubMed
    14. Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF. Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. J Invest Dermatol. 2020 02; 140(2):269-274. PMID: 31348921.
      View in: PubMed
    15. Osborne DG, Domenico J, Luo Y, Reid AL, Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA, Fujita M. Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Mol Carcinog. 2019 09; 58(9):1670-1679. PMID: 31099111.
      View in: PubMed
    16. Menon DR, Fujita M. A state of stochastic cancer stemness through the CDK1-SOX2 axis. Oncotarget. 2019 Apr 05; 10(27):2583-2585. PMID: 31080551.
      View in: PubMed
    17. Fujita M, Somasundaram V, Basudhar D, Cheng RYS, Ridnour LA, Higuchi H, Imadome K, No JH, Bharadwaj G, Wink DA. Role of nitric oxide in pancreatic cancer cells exhibiting the invasive phenotype. Redox Biol. 2019 04; 22:101158. PMID: 30852389.
      View in: PubMed
    18. Matsumoto A, Ito S, Wakamatsu K, Ichiba M, Vasiliou V, Akao C, Song BJ, Fujita M. Ethanol induces skin hyperpigmentation in mice with aldehyde dehydrogenase 2 deficiency. Chem Biol Interact. 2019 Apr 01; 302:61-66. PMID: 30721697.
      View in: PubMed
    19. Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res. 2018 12 01; 78(23):6561-6574. PMID: 30297536.
      View in: PubMed
    20. Armstrong AW, Chambers CJ, Maverakis E, Cheng MY, Dunnick CA, Chren MM, Gelfand JM, Wong DJ, Gibbons BM, Gibbons CM, Torres J, Steel AC, Wang EA, Clark CM, Singh S, Kornmehl HA, Wilken R, Florek AG, Ford AR, Ma C, Ehsani-Chimeh N, Boddu S, Fujita M, Young PM, Rivas-Sanchez C, Cornejo BI, Serna LC, Carlson ER, Lane CJ. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open. 2018 10 05; 1(6):e183062. PMID: 30646223.
      View in: PubMed
    21. Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE. ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol. 2018 12 20; 25(12):1456-1469.e6. PMID: 30293938.
      View in: PubMed
    22. Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF. Frontiers in pigment cell and melanoma research. Pigment Cell Melanoma Res. 2018 11; 31(6):728-735. PMID: 30281213.
      View in: PubMed
    23. Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the ß-Catenin Pathway in the Hair Follicle Bulge Stem Cells. J Invest Dermatol. 2018 03; 138(3):657-668. PMID: 29054607.
      View in: PubMed
    24. Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817. PMID: 27086916.
      View in: PubMed
    25. Li Y, Fujita M, Boraschi D. Endotoxin Contamination in Nanomaterials Leads to the Misinterpretation of Immunosafety Results. Front Immunol. 2017; 8:472. PMID: 28533772.
      View in: PubMed
    26. Pearson DR, Fujita M, High WA. Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course. J Mol Biomark Diagn. 2017 May; 8(3). PMID: 28758048.
      View in: PubMed
    27. Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget. 2016 Dec 20; 7(51):84594-84607. PMID: 27829238.
      View in: PubMed
    28. Dinarello CA, Nold-Petry C, Nold M, Fujita M, Li S, Kim S, Bufler P. Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol. 2016 05; 46(5):1067-81. PMID: 27060871.
      View in: PubMed
    29. Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, O'Connell RM. microRNAs in Psoriasis. J Invest Dermatol. 2016 Feb; 136(2):365-371. PMID: 26802234.
      View in: PubMed
    30. Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol. 2015 Sep; 135(9):2155-2161. PMID: 25947358.
      View in: PubMed
    31. Højen JF, Rasmussen TA, Andersen KL, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS, Dinarello CA, Tolstrup M. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. Mol Med. 2015 Apr 14; 21:337-45. PMID: 25879630.
      View in: PubMed
    32. Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, Kim S, Dinarello CA. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):2497-502. PMID: 25654981.
      View in: PubMed
    33. Snedecor ER, Sung CC, Moncayo A, Rothstein BE, Mockler DC, Tonnesen MG, Jones EC, Fujita M, Clark RA, Shroyer KR, Chen J. Loss of primary cilia in melanoma cells is likely independent of proliferation and cell cycle progression. J Invest Dermatol. 2015 May; 135(5):1456-1458. PMID: 25629424.
      View in: PubMed
    34. Chen HM, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015 Mar; 72(1):113-4. PMID: 25592113.
      View in: PubMed
    35. Nguyen N, Couts KL, Luo Y, Fujita M. Understanding melanoma stem cells. Melanoma Manag. 2015; 2(2):179-188. PMID: 26594315.
      View in: PubMed
    36. Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar; 135(3):842-850. PMID: 25350317.
      View in: PubMed
    37. Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, Bufler P, Norris D, Dinarello CA, Fujita M. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15178-83. PMID: 25294929.
      View in: PubMed
    38. Fujita M, Imadome K, Endo S, Shoji Y, Yamada S, Imai T. Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation. FEBS Lett. 2014 Aug 25; 588(17):3240-50. PMID: 25019574.
      View in: PubMed
    39. Luo Y, Nguyen N, Fujita M. Isolation of human melanoma stem cells using ALDH as a marker. Curr Protoc Stem Cell Biol. 2013 Sep 20; 26:3.8.1-3.8.10. PMID: 24510792.
      View in: PubMed
    40. Nguyen N, Luo Y, Fujita M. Aldehyde dehydrogenase isozymes: markers of cancer stem cells in human melanoma. Expert Rev Dermatol. 2013; 8(2):111-113. PMID: 26877760.
      View in: PubMed
    41. Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR. Combined anti-tumor necrosis factor-a therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol. 2012; 3:366. PMID: 23264777.
      View in: PubMed
    42. Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells. Chem Biol Interact. 2013 Feb 25; 202(1-3):2-10. PMID: 23159885.
      View in: PubMed
    43. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012 Oct; 30(10):2100-13. PMID: 22887839.
      View in: PubMed
    44. Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 2013 Feb; 133(2):518-27. PMID: 22931929.
      View in: PubMed
    45. Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450. PMID: 22622430.
      View in: PubMed
    46. Domenico J, Lucas JJ, Fujita M, Gelfand EW. Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status. Int Arch Allergy Immunol. 2012; 158(2):196-205. PMID: 22286752.
      View in: PubMed
    47. Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012 Feb 15; 1(2):92-100. PMID: 23213401.
      View in: PubMed
    48. Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 2012 Jan 01; 314(1):24-33. PMID: 22050907.
      View in: PubMed
    49. Jensen JD, Dunn JH, Luo Y, Liu W, Fujita M, Dellavalle RP. Ellagic acid inhibits melanoma growth in vitro. Dermatol Reports. 2011 Oct 05; 3(3):e36. PMID: 25386288.
      View in: PubMed
    50. Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, Fujita M. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1ß secretion. Biochem Biophys Res Commun. 2011 Oct 28; 414(3):551-6. PMID: 21982776.
      View in: PubMed
    51. Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One. 2011; 6(8):e24294. PMID: 21897876.
      View in: PubMed
    52. Prado R, Jensen JD, Okamoto M, Luo Y, Lewis KD, Fujita M. Metastatic melanoma manifesting with purulent nodules composed of neutrophils and melanoma cells. Eur J Dermatol. 2011 Jul-Aug; 21(4):642-3. PMID: 21840791.
      View in: PubMed
    53. Luo Y, Robinson S, Fujita J, Siconolfi L, Magidson J, Edwards CK, Wassmann K, Storm K, Norris DA, Bankaitis-Davis D, Robinson WA, Fujita M. Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One. 2011; 6(6):e20971. PMID: 21698244.
      View in: PubMed
    54. Prado R, Brice SL, Fukuda S, Hashimoto T, Fujita M. Paraneoplastic pemphigus herpetiformis with IgG antibodies to desmoglein 3 and without mucosal lesions. Arch Dermatol. 2011 Jan; 147(1):67-71. PMID: 21242397.
      View in: PubMed
    55. Anwar A, Norris DA, Fujita M. Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys. 2011 Apr 15; 508(2):198-203. PMID: 21167122.
      View in: PubMed
    56. Jensen JD, Fujita M, Dellavalle RP. Validation of psoriasis clinical severity and outcome measures: searching for a gold standard. Arch Dermatol. 2011 Jan; 147(1):95-8. PMID: 20855674.
      View in: PubMed
    57. Strahan JE, Chorny JA, Cohen JL, Fujita M. Combined multifocal indeterminate cell histiocytosis and basal cell carcinoma. Arch Dermatol. 2010 Mar; 146(3):346-7. PMID: 20231516.
      View in: PubMed
    58. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2010 Feb 26; 285(9):6477-88. PMID: 20038581.
      View in: PubMed
    59. Strahan JE, Fujita M. A violaceous nodule on the knee. Merkel cell carcinoma (MCC). Arch Dermatol. 2009 Jun; 145(6):715-20. PMID: 19528432.
      View in: PubMed
    60. Fujita M, High WA, Asgari S, Lewis KD, Gonzalez R. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30. PMID: 19335434.
      View in: PubMed
    61. Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr; 129(4):964-71. PMID: 18987671.
      View in: PubMed
    62. Goldstein NB, Johannes WU, Gadeliya AV, Green MR, Fujita M, Norris DA, Shellman YG. Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. J Invest Dermatol. 2009 Feb; 129(2):432-7. PMID: 18668139.
      View in: PubMed
    63. Anwar A, Gu M, Brady S, Qamar L, Behbakht K, Shellman YG, Agarwal R, Norris DA, Horwitz LD, Fujita M. Photoprotective effects of bucillamine against UV-induced damage in an SKH-1 hairless mouse model. Photochem Photobiol. 2008 Mar-Apr; 84(2):477-83. PMID: 18266821.
      View in: PubMed
    64. Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK, Franzusoff A, Norris DA, Fujita M. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol. 2007 Oct; 16(10):814-22. PMID: 17845213.
      View in: PubMed
    65. Riemann H, Loser K, Beissert S, Fujita M, Schwarz A, Schwarz T, Grabbe S. IL-12 breaks dinitrothiocyanobenzene (DNTB)-mediated tolerance and converts the tolerogen DNTB into an immunogen. J Immunol. 2005 Nov 01; 175(9):5866-74. PMID: 16237079.
      View in: PubMed
    66. Shellman YG, Park YL, Marr DG, Casper K, Xu Y, Fujita M, Swerlick R, Norris DA. Release of vascular endothelial growth factor from a human melanoma cell line, WM35, is induced by hypoxia but not ultraviolet radiation and is potentiated by activated Ras mutation. J Invest Dermatol. 2003 Oct; 121(4):910-7. PMID: 14632212.
      View in: PubMed
    Fujita's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)